Buspirone is NOT contraindicated in focal seizures
Buspirone (Buspar) does not have focal seizures listed as a contraindication in its FDA labeling. The official contraindications are limited to hypersensitivity to buspirone and concurrent use with MAOIs 1.
Key Points from FDA Labeling
The FDA label explicitly states buspirone is contraindicated only in:
- Patients hypersensitive to buspirone
- Concurrent use with MAOIs (or within 14 days of MAOI discontinuation)
- Use with reversible MAOIs like linezolid or IV methylene blue 1
Notably absent from contraindications: any mention of seizures or epilepsy.
Important Caveats About Seizure Risk
While not contraindicated, clinicians should be aware of several concerns:
Lack of Anticonvulsant Properties
Buspirone fundamentally differs from benzodiazepines—it lacks anticonvulsant activity 2, 3, 4. This means:
- It provides no seizure protection
- It cannot substitute for benzodiazepines in seizure management
- Patients requiring anxiolysis with seizure protection need alternative agents
Potential Proconvulsant Effects
The evidence suggests possible seizure-lowering effects:
- Case report evidence: One documented case of generalized tonic-clonic seizure approximately 36 hours after buspirone overdose 5
- Animal data: Buspirone antagonized the protective effects of anticonvulsants (valproate, carbamazepine, phenytoin) against chemically and electrically-induced seizures in mice 6
- Serotonin syndrome warning: The FDA label warns that serotonin syndrome (which can include seizures as a symptom) may occur with buspirone, particularly with concomitant serotonergic drugs 1
Clinical Implications
For patients with focal seizures requiring anxiolytic therapy:
- Buspirone can be used, but with heightened awareness
- Ensure adequate antiseizure medication coverage is maintained
- Monitor for breakthrough seizures, particularly during buspirone initiation
- Consider alternative anxiolytics if seizure control is tenuous
- Avoid combining with other serotonergic agents that might precipitate serotonin syndrome
The decision to use buspirone in focal epilepsy should weigh:
- Current seizure control stability
- Adequacy of baseline antiseizure medication regimen
- Presence of other serotonergic medications
- Alternative anxiolytic options (though benzodiazepines carry their own risks)
The absence of a formal contraindication does not equal complete safety—buspirone's lack of anticonvulsant properties and potential proconvulsant effects in overdose warrant cautious use in epilepsy patients, but it remains a permissible option when clinically appropriate 1, 5.